Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targets SACRAMENTO, Calif., Sept. 22, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI), a...